Sign In
Buy IONS
$51.77
-1.51 (-2.83%)
At Close: Jul 31, 2026
IONS Beats Q2 Earnings & Sales Estimates, Reiterates '26 Outlook
02:50pm, Thursday, 30'th Jul 2026
Ionis beats Q2 revenues and earnings estimates as commercial growth offsets tough comparisons, while reaffirming its 2026 outlook.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONS
10:00am, Thursday, 30'th Jul 2026
NEW YORK, July 30, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Ionis Pharmaceuticals, Inc. ("Ionis" or the "Company") (NASDAQ: IONS). Such investors are advi
Ionis Pharmaceuticals, Inc. (IONS) Q2 2026 Earnings Call Transcript
02:33pm, Wednesday, 29'th Jul 2026
Ionis Pharmaceuticals, Inc. (IONS) Q2 2026 Earnings Call Transcript
Ionis Pharmaceuticals Q2 Earnings Call Highlights
12:06pm, Wednesday, 29'th Jul 2026
Ionis Pharmaceuticals NASDAQ: IONS reported second-quarter revenue growth driven by commercial products and partnered research programs, while highlighting the recent U.S. approval and early launch pr
Compared to Estimates, Ionis Pharmaceuticals (IONS) Q2 Earnings: A Look at Key Metrics
10:31am, Wednesday, 29'th Jul 2026
The headline numbers for Ionis Pharmaceuticals (IONS) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall St
Ionis Pharmaceuticals (IONS) Reports Q2 Loss, Tops Revenue Estimates
09:26am, Wednesday, 29'th Jul 2026
Ionis Pharmaceuticals (IONS) came out with a quarterly loss of $0.43 per share versus the Zacks Consensus Estimate of a loss of $0.89. This compares to earnings of $0.86 per share a year ago.
Ionis announces Dr. Frank Bennett, chief scientific officer, to retire
07:05am, Wednesday, 29'th Jul 2026
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that Frank Bennett, Ph.D., executive vice president and chief scientific officer, will retire effective Fe
Ionis reports second quarter 2026 financial results and highlights progress on key programs
07:00am, Wednesday, 29'th Jul 2026
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the “Company”) today reported financial results and provided key updates for the second quarter ended June 30, 2026.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONS
05:03pm, Tuesday, 28'th Jul 2026
NEW YORK, July 28, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Ionis Pharmaceuticals, Inc. (“Ionis” or the “Company”) (NASDAQ: IONS). Such investor
Ionis Pharmaceuticals, Inc. (IONS) Faces Investor Scrutiny After Surprise Trial Failure Drives Stock Down 23% – HBSS
12:46pm, Tuesday, 28'th Jul 2026
SAN FRANCISCO, July 28, 2026 (GLOBE NEWSWIRE) -- Investors in Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) saw the price of their shares plunge $20.19 (-23%) on July 9, 2026 after the commercial stage b
Entropy Technologies LP Makes New $2.04 Million Investment in Ionis Pharmaceuticals, Inc. $IONS
04:37am, Monday, 27'th Jul 2026
Entropy Technologies LP purchased a new stake in Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) during the first quarter, according to the company in its most recent disclosure with the Securities and Exc
Ionis Pharmaceuticals, Inc. (IONS) Faces Investor Scrutiny After Surprise Trial Failure Drives Stock Down 23% - HBSS
11:30am, Thursday, 23'rd Jul 2026
SAN FRANCISCO, July 23, 2026 /PRNewswire/ -- Investors in Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) saw the price of their shares plunge $20.19 (-23%) on July 9, 2026 after the commercial stage biote
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONS
10:00am, Thursday, 23'rd Jul 2026
NEW YORK, July 23, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Ionis Pharmaceuticals, Inc. ("Ionis" or the "Company") (NASDAQ: IONS). Such investors are advise
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONS
01:27pm, Tuesday, 21'st Jul 2026
NEW YORK, July 21, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Ionis Pharmaceuticals, Inc. (“Ionis” or the “Company”) (NASDAQ: IONS). Such invest
Amova Asset Management Americas Inc. Has $6.13 Million Stock Position in Ionis Pharmaceuticals, Inc. $IONS
03:17am, Tuesday, 21'st Jul 2026
Amova Asset Management Americas Inc. reduced its stake in shares of Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) by 12.7% in the undefined quarter, according to the company in its most recent Form 13F f
